United Therapeutics and Gilead Sciences are identified as major players in the therapeutics industry.
1 report, 1 independent
Updated Jul 16
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
United Therapeutics and Gilead Sciences are identified as major players in the therapeutics industry.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
United Therapeutics
biotech company based in Silver Spring, Maryland, United States
-
Gilead Sciences
American company
- Required regulatory filings regarding institutional holdings were made by Gilead Sciences, Inc. with the Securities and Exchange Commission on June 11, 2026.
- A pilot program is underway involving the federal government, Benue State, and Gilead Sciences, with the state participating in the drug supply management.
Related events
- Gilead Sciences acquired Arcellx and presented priorities at a Wells Fargo conference, while also discussing submissions with the FDA and CDC.
- GSK and EXEL are developing treatments for PBC, and the FDA granted accelerated approval to Gilead Sciences for related therapies.
- Executive leadership experience gained at Gilead Sciences, involving Cocrystal Pharma.
- FDA granted designation for a drug under Gibbs' leadership, involving GSK and Gilead Sciences.
- A conference involving Gilead Sciences and Bayer was held in Philadelphia on September 10, 2026.
Coverage
Newest first; wire copies grouped- StockStoryQ1 Earnings Roundup: Gilead Sciences (NASDAQ:GILD) And The Rest Of The Therapeutics Segment As the Q1 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst perfor